A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Clinical trial NCT05276726 · RECRUITING

Trial details

NCT number: NCT05276726
Sponsor: Allist Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2022-08-17
Primary completion: 2027-08-01
Enrollment: 104

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.